-
1
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1...
Published 2025-01-01Subjects: “…advanced solid tumors…”
Get full text
Article -
2
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budi...
Published 2024-10-01Subjects: “…advanced solid tumors…”
Get full text
Article